New antibiotics still a decade away unless policymakers, investors step up, AMR Action Fund CEO warns
A “broken” investment model means a new antibiotic may not reach the market for another decade, according to the head of a $1 billion Big Pharma-backed fund focused on the growing threat of drug-resistant bacteria.
Urgent market reform is needed to encourage investment and expand the razor-thin pipeline of antibiotics in development, AMR Action Fund CEO Henry Skinner, Ph.D., told Fierce Biotech in an interview. The fund was set up by a who’s who of leading biopharma companies with a mission of bringing up to four new antibiotics to patients by 2030, but even this ambitious goal is just “buying some time,” Skinner said.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.